

Certificate of Analysis

www.tocris.com

Product Name: Enoximone

Catalog No.: 1693


Batch No.: 1

CAS Number: 77671-31-9

IUPAC Name: 1,3-Dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₁₂H₁₂N₂O₂S
Batch Molecular Weight: 248.3
Physical Appearance: White solid
Solubility: DMSO to 100 mM
Storage: Store at +4°C
Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 99.8% purity
¹H NMR: Consistent with structure
Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	58.05	4.87	11.28
Found	57.93	4.88	11.17

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: Enoximone

Catalog No.: 1693

Batch No.: 1

CAS Number: 77671-31-9

IUPAC Name: 1,3-Dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one

Description:

Inhibitor of type III phosphodiesterase (PDE3). Increases intracellular cyclic AMP (cAMP) concentrations and enhances myocardial contractility. Also induces concentration-dependent vasodilation in vitro.

Physical and Chemical Properties:


Batch Molecular Formula: C₁₂H₁₂N₂O₂S

Batch Molecular Weight: 248.3

Physical Appearance: White solid

Minimum Purity: >99%

Batch Molecular Structure:



Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Vroom et al (1996) Effect of phosphodiesterase inhibitors on human arteries *in vitro*. Br.J.Anaesth. **76** 122. PMID: 8672353.

Pacher and Stanek (1999) Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience. Eur.J.Heart Fail. **1** 263. PMID: 10935673.

Jung et al (2005) Pharmacological effects of AT122-107 [2-(2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino)-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester], a novel dual pharmacophore, on myocyte calcium cycling and contractility. J.Pharmacol.Exp.Ther. **312** 517. PMID: 15550574.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel: +1 612 379 2956